The outbreak was identified when suspected measles cases had been reported by the local residents in the surrounding areas, highlighting pockets of under-vaccinated populations. According to WHO/UNICEF 2018 estimates, measles first dose vaccination coverage is relatively high (88%), and slightly lower for the second dose (77%). However, this does not reflect the vaccination coverage of incoming refugees.
The link below provides details of the 15 reported cases.
Of the 124 confirmed cases, 105 were in Mexico City, 18 in Mexico State, and one in Campeche State; the following is a summary of the epidemiological situation in each:
In response to the positive RT-PCR results, the EPHI and Ministry of Health performed an in-depth investigation and response, supported by partners including WHO.
The cases were identified through a cross-border rapid response team investigation mounted in response to the recently declared outbreak in bordering Moyo district, Uganda. During the investigation, the team collected 41 blood samples from five villages which were in close proximity to the bordering Moyo district, Uganda. Of the 41 individuals whose samples were collected, nine (22%) had history of fever, but none had history of jaundice. The individuals represented a spectrum of occupations typical for the area (farming, forestry, homemaker, soldier). Most of the individuals investigated were between 20-45 years of age, and 18 (44%) of these individuals were female.
Dengue epidemics in these territories usually occur when there is a shift in the predominant circulating DENV serotype, and non-immune populations (e.g., tourists, new immigrants, or people not previously exposed to the circulating serotypes) are exposed to the new serotype through human movements within the territories or across neighboring countries. Local transmission occurs through the Aedes mosquito vector present on the islands and in French Guiana.
Substantial surveillance, pathogen detection, and clinical management activities are currently ongoing, including validating alerts, following remaining contacts who were potentially exposed to the virus, supporting rapid diagnostics of suspected cases, and working with community members to strengthen surveillance on people who pass away in the communities. As of 25 February, 510 contacts are currently under surveillance, of which 97% were followed daily in the last seven days. In the last seven days, more than 5100 alerts per day were reported and investigated, of which over 400 alerts (including ~70 community deaths) were validated as suspected EVD cases; requiring laboratory testing and specialized care within the established Ebola treatment and transit centres. On average, suspect cases stay in these facilities for three days before EVD can be definitively ruled out (i.e. after two negative polymerase chain reaction tests 48 hours apart), while care is provided for their illness under isolation precautions. Timely testing of suspected cases continues to be provided across 11 operational laboratories deployed in cities that have been affected by the outbreak. From 17 to 23 February, more than 3600 samples were tested.